Shaikh Samiullah1, Devrajani Bikharam. 1. Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro/Hyderabad 71000, Pakistan. shaikhsamiullah@yahoo.com
Abstract
AIM: To observe the efficacy of peg-interferon in the treatment of hepatitis delta virus (HDV) and to identify the factors that would be predictive of the sustained viral response (SVR). METHODS: This prospective study was conducted in Medical Unit IV of the Liaquat University of Medical and Health Sciences Hospital Jamshoro from June 2008 to September 2011. This study cohort included all patients of either sex who presented during this time with hepatitis B surface antigen positivity, hepatitis B virus DNA > 20,000 IU/mL, serum glutamic pyruvic transaminase (SGPT) > 2(upper limit of normal), HDV-RNA positivity with fibrosis stage ≥ 2. Informed consent was obtained from each of these individuals. Patients were diagnosed with hepatitis D on the basis of detectable viral antibodies and the presence of HDV-RNA in their serum. A liver biopsy was performed in all cases and fibrosis staging was performed in accordance with the METAVIR scoring system. All eligible patients were administered peg-interferon at a weekly dosage of 1.5 μg/kg body weight for 48 wk. HDV-RNA was assayed at the end of this treatment period and again at 24 wk later. A biochemical response was determined by a normalization of SGPT at the end of the treatment or during follow up. The end of treatment response was defined by a HDV-RNA negative status. A sustained virological response was defined by undetectable serum HDV-RNA at six months after the end of treatment. RESULTS: Among the 277 patients enrolled in our present study, 238 completed a course of peg-interferon therapy of which 180 (75.6%) were male and 58 (24.4%) female. Biochemical responses were achieved in 122/238 (51.3%) patients. End of treatment responses were achieved in 71/238 (29.8%) cases. A SVR was achieved in 70 of these patients (29.4%). A strong association was found between the SVR and the end of treatment responses (P = 0.001), biochemical responses (P = 0.001) and the degree of fibrosis (P = 0.002). CONCLUSION: Peg-interferon therapy can induce remission in nearly one third of patients harboring HDV.
AIM: To observe the efficacy of peg-interferon in the treatment of hepatitis delta virus (HDV) and to identify the factors that would be predictive of the sustained viral response (SVR). METHODS: This prospective study was conducted in Medical Unit IV of the Liaquat University of Medical and Health Sciences Hospital Jamshoro from June 2008 to September 2011. This study cohort included all patients of either sex who presented during this time with hepatitis B surface antigen positivity, hepatitis B virus DNA > 20,000 IU/mL, serum glutamic pyruvic transaminase (SGPT) > 2(upper limit of normal), HDV-RNA positivity with fibrosis stage ≥ 2. Informed consent was obtained from each of these individuals. Patients were diagnosed with hepatitis D on the basis of detectable viral antibodies and the presence of HDV-RNA in their serum. A liver biopsy was performed in all cases and fibrosis staging was performed in accordance with the METAVIR scoring system. All eligible patients were administered peg-interferon at a weekly dosage of 1.5 μg/kg body weight for 48 wk. HDV-RNA was assayed at the end of this treatment period and again at 24 wk later. A biochemical response was determined by a normalization of SGPT at the end of the treatment or during follow up. The end of treatment response was defined by a HDV-RNA negative status. A sustained virological response was defined by undetectable serum HDV-RNA at six months after the end of treatment. RESULTS: Among the 277 patients enrolled in our present study, 238 completed a course of peg-interferon therapy of which 180 (75.6%) were male and 58 (24.4%) female. Biochemical responses were achieved in 122/238 (51.3%) patients. End of treatment responses were achieved in 71/238 (29.8%) cases. A SVR was achieved in 70 of these patients (29.4%). A strong association was found between the SVR and the end of treatment responses (P = 0.001), biochemical responses (P = 0.001) and the degree of fibrosis (P = 0.002). CONCLUSION:Peg-interferon therapy can induce remission in nearly one third of patients harboring HDV.
Authors: H Wedemeyer; K H Böker; K Pethig; D R Petzold; P Flemming; H L Tillmann; J Vollmar; M Bastürk; E Goldmann; K E Griffin; A Haverich; M P Manns Journal: Transplantation Date: 1999-11-27 Impact factor: 4.939
Authors: Heiner Wedemeyer; Cihan Yurdaydìn; George N Dalekos; Andreas Erhardt; Yilmaz Çakaloğlu; Halil Değertekin; Selim Gürel; Stefan Zeuzem; Kalliopi Zachou; Hakan Bozkaya; Armin Koch; Thomas Bock; Hans Peter Dienes; Michael P Manns Journal: N Engl J Med Date: 2011-01-27 Impact factor: 91.245
Authors: Grazia Anna Niro; Antonina Smedile; Antonio Massimo Ippolito; Alessia Ciancio; Rosanna Fontana; Antonella Olivero; Maria Rosa Valvano; Maria Lorena Abate; Domenica Gioffreda; Gian Paolo Caviglia; Mario Rizzetto; Angelo Andriulli Journal: J Hepatol Date: 2010-07-29 Impact factor: 25.083
Authors: C Yurdaydin; H Bozkaya; F O Onder; H Sentürk; H Karaaslan; M Akdoğan; H Cetinkaya; E Erden; O Erkan-Esin; K Yalçin; A M Bozdayi; R F Schinazi; J L Gerin; O Uzunalimoğlu; A Ozden Journal: J Viral Hepat Date: 2008-04 Impact factor: 3.728
Authors: T Heller; Y Rotman; C Koh; S Clark; V Haynes-Williams; R Chang; R McBurney; P Schmid; J Albrecht; D E Kleiner; M G Ghany; T J Liang; J H Hoofnagle Journal: Aliment Pharmacol Ther Date: 2014-05-11 Impact factor: 8.171